Beam Therapeutics Inc
NASDAQ:BEAM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Beam Therapeutics Inc
Stock-Based Compensation
Beam Therapeutics Inc
Stock-Based Compensation Peer Comparison
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Beam Therapeutics Inc
NASDAQ:BEAM
|
Stock-Based Compensation
$98.7m
|
CAGR 3-Years
86%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$782m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$788m
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$650.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Beam Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
98.7m
USD
Based on the financial report for Dec 31, 2023, Beam Therapeutics Inc's Stock-Based Compensation amounts to 98.7m USD.
What is Beam Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
70%
Over the last year, the Stock-Based Compensation growth was 17%. The average annual Stock-Based Compensation growth rates for Beam Therapeutics Inc have been 86% over the past three years , 70% over the past five years .